{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Baxter International, Inc.
Baxter International Opens with 15.25% Gap Down Amid Market Concerns
Baxter International, Inc. experienced a notable decline in its stock performance, contrasting with the stable S&P 500. The company has faced a significant drop over the past month, with a market capitalization of approximately USD 16.61 billion and a premium P/E ratio, alongside a moderate debt-to-equity ratio.
Baxter International Hits 52-Week Low at $18.44 Amidst Declining Sales
Baxter International, Inc. has reached a new 52-week low, reflecting a difficult year marked by a significant stock price decline. The company has reported negative results for three consecutive quarters, with declining net sales and profitability, alongside a high debt-to-EBITDA ratio, indicating ongoing financial challenges.
Is Baxter International, Inc. technically bullish or bearish?
As of July 14, 2025, Baxter International, Inc. is in a bearish trend, indicated by negative signals from MACD and moving averages, despite a bullish weekly RSI, and has significantly underperformed the S&P 500 with year-to-date and one-year returns of -18.76% and -39.83%, respectively.
Is Baxter International, Inc. overvalued or undervalued?
As of February 8, 2024, Baxter International, Inc. is considered overvalued with a P/E ratio of 31 compared to its peer Align Technology's 20.46, and has underperformed the S&P 500 with a year-to-date return of -18.76% and a three-year decline of 59.28%.
Is Baxter International, Inc. technically bullish or bearish?
As of June 9, 2025, Baxter International, Inc. exhibits a mildly bearish trend, influenced by mixed signals from indicators like MACD showing mild bullishness, while Bollinger Bands and moving averages indicate bearishness.
Is Baxter International, Inc. overvalued or undervalued?
As of February 8, 2024, Baxter International, Inc. is considered overvalued with a risky valuation grade, reflected in its high P/E ratio of 31 and poor stock performance, including a 1-year return of -12.54%, compared to its peers like Agilent Technologies and GE Healthcare.
Who are in the management team of Baxter International, Inc.?
As of March 2022, Baxter International, Inc.'s management team includes Mr. Jose Almeida as Chairman, President, and CEO, and Mr. Thomas Stallkamp as Lead Independent Director, along with several Independent Directors.
What does Baxter International, Inc. do?
Baxter International, Inc. specializes in renal and hospital products within the Pharmaceuticals & Biotechnology industry, with a recent net sales of $2.625 billion and a market cap of approximately $20.62 billion. Key financial metrics include a P/E ratio of 31.00 and a dividend yield of 1.97%.
How big is Baxter International, Inc.?
As of Jun 18, Baxter International, Inc. has a market capitalization of $20.62 billion, with net sales of $11.89 billion and a net profit of -$674 million over the last four quarters.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
